GlassScriptPhysician profile
Kevin Lee Borst
NPI 1982818506
$4,098.15
in general payments reported to CMS, 2019-2025
20 companies · $1,087 in 2025
The $1,087 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $564 · 2021: $289 · 2022: $496 · 2023: $442 · 2024: $499 · 2025: $1,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403 · Honoraria: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,402.92 |
| Honoraria | $625.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $963.31 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $776.71 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $694.08 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Chiesi USA, INC. | $625.00 | 2025 | Myalept |
| Medtronic Minimed, INC. | $214.60 | 2019-2020 | |
| Dexcom, INC. | $179.26 | 2019-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $151.68 | 2019 | |
| Medtronic, INC. | $104.48 | 2021-2025 | Minimed 780g |
| Genzyme Corporation | $72.00 | 2020 | |
| Ascendis Pharma Endocrinology INC | $54.14 | 2025 | Yorvipath |
| Amryt Pharma Holdings LTD | $45.07 | 2023 | Myalept |
| Xeris Pharmaceuticals, INC. | $39.77 | 2022-2023 | Gvoke Hypopen |
| Rgh Enterprises LLC | $37.89 | 2022-2023 | |
| Sequel Med Tech, LLC | $34.19 | 2025 | Twiist |
| Insulet Corporation | $27.91 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $20.03 | 2020 | |
| Mannkind Corporation | $14.95 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.68 | 2019 | |
| Neurocrine Biosciences, INC. | $14.54 | 2025 | |
| Glaxosmithkline, LLC. | $13.86 | 2024 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Borst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.